Trial Profile
Ibrutinib toxicity review from FDA Adverse Event Reporting System (FAERS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jun 2018
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Cancer
- Focus Adverse reactions
- 15 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.